Artivion (AORT) Q3 2026 Earnings Call Transcript

Artivion reported Q3 2026 revenue of $123.8 million, up 9% year over year on a constant-currency basis, while adjusted EBITDA fell 8% to $22.5 million and its margin declined 350 basis points to 18.2%. Gross margin dropped to 61.4% from 65.6%, and free cash flow was negative $17.6 million, including a $13.3 million AMDS milestone payment and about $2 million in integration expenses. The company narrowed 2026 revenue guidance to $484 million–$492 million and adjusted EBITDA guidance to $93 million–$98 million; management expects PerClot’s agreement expiration to be a 2-point revenue-growth and 4-point EBITDA-growth headwind in 2027.

Analysis

This is a weak read-through for Baxter International (BAX), not a standalone earnings signal: the PerClot transition agreement ends in February 2027, but the call gives no contract value, revenue contribution, or margin economics for Baxter. Do not translate Artivion’s expected 2027 growth headwind into a matching Baxter loss; the disclosed impact is specific to Artivion and may be immaterial to Baxter. Verify Baxter’s filing or commentary before assigning exposure.

The more consequential risk sits with Artivion: manufacturing costs and acquisition spending are pressuring margins while leverage is 3.5x, and management expects 2027 EBITDA to be neutral. The bull case relies on NEXUS adoption and improved unit costs; neither is yet demonstrated at scale. AMDS implants progressing while starter-set purchases lag also suggests clinical interest is not converting smoothly into commercial revenue. A slower NEXUS ramp or continued hospital purchasing friction would leave less cash-flow cushion than the product pipeline narrative implies.

Near-term catalysts are the Nov. 19 ARTIZEN data presentation and the Jan. 2027 NEXUS launch; the data are early, and launch revenue should be judged by adoption rather than training interest. Over 1–3 months, track purchase orders, NEXUS case cadence, and gross-margin recovery. Over 6–18 months, PerClot’s exit creates a known Artivion comparison/headwind, while trial enrollment and debt reduction remain execution risks. Contrarian point: bullish pipeline claims may be over-weighted relative to procurement friction, ramp costs, and leverage—but this transcript alone does not justify a BAX position.

Key Decisions for Investors

• No BAX trade on this disclosure alone: the agreement’s Baxter economics are undisclosed, so treat any revenue or earnings impact as an unquantified watch item.
• Monitor Baxter filings and management commentary for the PerClot agreement’s scale, termination economics, and any replacement manufacturing or supply arrangement.
• For Artivion, watch NEXUS launch cases and gross margin through the first half of 2027; weaker-than-expected conversion or no margin improvement would challenge the ramp thesis.
• Review the Nov. 19 ARTIZEN presentation as a clinical catalyst, but do not treat early single-arm data as proof of commercial adoption or eventual approval.